News & Updates

Tofacitinib may promote HBV reactivation in certain RA patients
Tofacitinib may promote HBV reactivation in certain RA patients
24 Sep 2021

Use of tofacitinib for rheumatoid arthritis (RA) may lead to reactivation of hepatitis B virus (HBV), especially among hepatitis B surface antigen-positive (HBsAg+) and HBsAg-negative/hepatitis B core antibody-positive (HBsAg–/HBcAb+) patients, according to a study from Taiwan.

Tofacitinib may promote HBV reactivation in certain RA patients
24 Sep 2021